Abstract
Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.
Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)
Current Drug Targets
Title:Matrix Metalloproteinases as Drug Targets in Preeclampsia
Volume: 14 Issue: 3
Author(s): Ana C.T. Palei, Joey P. Granger and Jose E. Tanus-Santos
Affiliation:
Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)
Abstract: Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.
Export Options
About this article
Cite this article as:
C.T. Palei Ana, P. Granger Joey and E. Tanus-Santos Jose, Matrix Metalloproteinases as Drug Targets in Preeclampsia, Current Drug Targets 2013; 14 (3) . https://dx.doi.org/10.2174/1389450111314030004
DOI https://dx.doi.org/10.2174/1389450111314030004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Sleep in Interstitial Lung Disease
Current Respiratory Medicine Reviews Search for Obesity Drugs: Targeting Central and Peripheral Pathways
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Impact of Asymmetric Dimethylarginine (ADAMA), the Endogenous Nitric Oxide (NO) Synthase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage
Current Pharmaceutical Design Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy
Current Pharmaceutical Design Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk)]
Current Pharmaceutical Design Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery